BRASILIA (Reuters) – The Brazilian pharmaceutical company that will make Russia’s Sputnik V vaccine against COVID-19 expects regulatory approval for Phase III tests by this week or early next at the latest, its Chief Executive Officer Fernando Marques said on Tuesday.
Marques said the strong efficacy results from late stage trials in Russia, published on Tuesday by The Lancet – 91.6% effective against symptomatic COVID-19 – will help speed up approval in Brazil sought by his firm União Quimica.
The Brazilian pharmaceutical company that will make Russia's Sputnik V vaccine against COVID-19 expects regulatory approval for Phase III tests by this week or early next at the latest, its Chief Executive Officer Fernando Marques said on Tuesday.
[uam ad id= 317182 ]
RIO DE JANEIRO, BRAZIL - The Brazilian pharmaceutical company that will make Russia’s Sputnik V vaccine against COVID-19 expects regulatory approval for Phase III tests by this week or early next week at the latest, Chief Executive Officer Fernando Marques said on Tuesday, February 2nd.
Marques said the strong efficacy results from late stage trials in Russia, published on Tuesday by The Lancet - 91.6% effective against symptomatic COVID-19 - will help speed up approval in Brazil sought by his firm Subscribe to our Premium Membership Plan. Already Subscribed? Login Here
By Reuters Staff
1 Min Read
BRASILIA, Feb 2 (Reuters) - The Brazilian pharmaceutical company that will make Russia’s Sputnik V vaccine against COVID-19 expects regulatory approval for Phase III tests by this week or early next at the latest, its Chief Executive Officer Fernando Marques said on Tuesday.
Marques said the strong efficacy results from late stage trials for Sputnik V in Russia published on Tuesday by The Lancet will help speed up approval in Brazil sought by his company, Uniao Quimica. He expects production to start in April and reach 8 million doses a month by May, for sale in Brazil and neighboring countries.